文献速递骨质疏松与钙磷/甲状旁腺

畸形性骨炎患者肾结石与高草酸尿症患病率增加

Increased Prevalence of Nephrolithiasis and Hyperoxaluria in Paget Disease of Bone.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该横断面多中心研究在意大利代谢性骨病转诊中心比较了708例畸形性骨炎(PDB)患者与1803例对照的原发性甲状旁腺功能亢进症(HPTH)和肾结石(NL)患病率,并在无HPTH人群中评估NL代谢危险因素;PDB患者HPTH和NL患病率均高于对照(P < 0.01),高草酸尿症患病率在PDB合并NL者中高于单纯NL者、在无NL的PDB者中高于对照(P = 0.01)。

要点

  • PDB患者原发性HPTH和NL患病率均高于对照(P < 0.01)。
  • NL复发在多骨型PDB患者中更常见。
  • 约半数无NL的PDB患者存在1项或以上NL相关代谢危险因素。

核心结论

  • NL和HPTH是PDB常见的代谢并发症。

研究设计与样本

  • 横断面多中心研究,研究1比较708例PDB患者与1803例对照,研究2评估97例PDB合并NL、219例PDB无NL、364例NL无PDB及219例对照(均无HPTH)的NL代谢危险因素。

主要发现

  • PDB患者原发性HPTH和NL患病率均高于对照(P < 0.01)。
  • NL复发在多骨型PDB患者中更常见。
  • 约半数无NL的PDB患者存在1项或以上NL相关代谢危险因素。
  • 高草酸尿症患病率在PDB合并NL患者中高于NL无PDB患者(P = 0.01),在PDB无NL患者中高于对照(P = 0.01)。
  • PDB合并高草酸尿症患者距末次氨基双膦酸盐治疗的时间间隔更长。

临床怎么用

  • 作者认为应对PDB患者评估NL发生情况,尤其多骨型疾病和/或氨基双膦酸盐治疗后患者,以实施适当预防策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Nephrolithiasis (NL) and primary hyperparathyroidism (HPTH) are metabolic complications of Paget disease of bone (PDB), but recent data regarding their prevalence in PDB patients are lacking. OBJECTIVES: Study 1: To compare the prevalence of primary HPTH and NL in 708 patients with PDB and in 1803 controls. Study 2: To evaluate the prevalence of NL-metabolic risk factors in 97 patients with PDB and NL, 219 PDB patients without NL, 364 NL patients without PDB, and 219 controls, all of them without HPTH. DESIGN: Cross-sectional multicentric study. SETTING: Italian referral centers for metabolic bone disorders. PARTICIPANTS: Patients with PDB from the Associazione Italiana malati di osteodistrofia di Paget registry. Participants in the Olivetti Heart and the Siena Osteoporosis studies. MAIN OUTCOME MEASURES: HPTH; NL; NL-metabolic risk factors. RESULTS: Patients with PDB showed higher prevalence of primary HPTH and NL compared with controls (P < 0.01). The NL recurrence occurs more frequently in patients with polyostotic PDB. About one-half of patients with PDB but without NL showed 1 or more NL-related metabolic risk factors. The hyperoxaluria (HyperOx) prevalence was higher in patients with PDB and NL compared with patients with NL but without PDB and in patients with PDB without NL compared with controls (P = 0.01). Patients with PDB and HyperOx showed a longer lapse of time from the last aminobisphosphonate treatment. CONCLUSIONS: NL and HPTH are frequent metabolic complication of PDB. The NL occurrence should be evaluated in patients with PDB, particularly in those with polyostotic disease and/or after aminobisphosphonate treatment to apply an adequate prevention strategy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rendina D, De Filippo G, Merlotti D, et al. Increased Prevalence of Nephrolithiasis and Hyperoxaluria in Paget Disease of Bone. J Clin Endocrinol Metab. 2020. PMID: 32827434. doi:10.1210/clinem/dgaa576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。